{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:06:06Z","timestamp":1772114766385,"version":"3.50.1"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The last decade has witnessed tremendous advances in revealing an important role for the interleukin (IL)-17 cytokine family in the pathogenesis of spondyloarthritis (SpA). Although most attention has been focused on IL-17A, a potential role of other IL-17 family members in inflammation and tissue remodelling is emerging. Herein, I review recent studies covering the role of IL-17B-F cytokines in the pathogenesis of SpA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several recent studies provided new insights into the cellular source, regulation and function of IL-17F. IL-17F\/IL-17A expression ratio is higher in psoriatic skin compared to SpA synovitis. IL-17F-expressing T cells produce different proinflammatory mediators than IL-17A-expressing cells, and IL-17F and IL-17A signal through different receptor complex. Dual IL-17A and IL-17F neutralization resulted in greater suppression of downstream inflammatory and tissue remodelling responses. Furthermore, there is additional evidence of IL-23-independent IL-17 production. In contrast to IL-17A, IL-17F and IL-17C, which play proinflammatory roles in skin and joint inflammation, an anti-inflammatory function is proposed for IL-17D. An increase in IL-17E is associated with subclinical gut microbiome alterations after anti-IL-17A therapy in SpA patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>IL-17 family cytokines may act as agonists or antagonists to IL-17A contributing in concert to local inflammatory responses. Understanding their function and identifying their cellular sources, and molecular mechanisms driving their expression will be the key to designing rational therapies in SpA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000805","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T06:30:46Z","timestamp":1621319446000},"page":"333-340","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis"],"prefix":"10.1097","volume":"33","author":[{"given":"Nataliya","family":"Yeremenko","sequence":"first","affiliation":[{"name":"Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology and Rheumatology"},{"name":"Department of Experimental Immunology, Amsterdam Institute for Infection & Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in Patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a Phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with nonradiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52\u200aweeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R14-20250526","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.201111","article-title":"Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies","author":"Schett","year":"2021","journal-title":"J Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250526","first-page":"375","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","article-title":"Antiinterleukin-23 agents for the treatment of ulcerative colitis","volume":"20","author":"Hanzel","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1073\/pnas.97.2.773","article-title":"Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1074\/jbc.M008289200","article-title":"IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1","volume":"276","author":"Lee","year":"2001","journal-title":"J Biol Chem"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.4049\/jimmunol.167.8.4137","article-title":"Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production","volume":"167","author":"Starnes","year":"2001","journal-title":"J Immunol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.immuni.2008.12.010","article-title":"Interleukin-17A and interleukin-17F: a tale of two cytokines","volume":"30","author":"Dubin","year":"2009","journal-title":"Immunity"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coi.2009.03.001","article-title":"Transcriptional regulatory networks in Th17 cell differentiation","volume":"21","author":"Zhou","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"585134","DOI":"10.3389\/fimmu.2020.585134","article-title":"Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling","volume":"11","author":"Cole","year":"2020","journal-title":"Front Immunol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Kjer-Nielsen","year":"2012","journal-title":"Nature"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nature01433","article-title":"Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1","volume":"422","author":"Treiner","year":"2003","journal-title":"Nature"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/jid.2014.261","article-title":"The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Investig Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3899\/jrheum.151133","article-title":"Involvement of mucosal-associated invariant T cells in ankylosing spondylitis","volume":"43","author":"Hayashi","year":"2016","journal-title":"J Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"e000821","DOI":"10.1136\/rmdopen-2018-000821","article-title":"MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?","volume":"4","author":"Toussirot","year":"2018","journal-title":"RMD Open"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis gammadeltaT-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mi.2013.122","article-title":"IL-17-producing NKT cells depend exclusively on IL-7 for homeostasis and survival","volume":"7","author":"Webster","year":"2014","journal-title":"Mucosal Immunol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41385-019-0212-y","article-title":"Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response","volume":"13","author":"Hassane","year":"2020","journal-title":"Mucosal Immunol"},{"key":"R41-20250526","first-page":"369","article-title":"Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis","volume":"22","author":"Yoshiga","year":"2008","journal-title":"Int J Mol Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.4049\/jimmunol.1202495","article-title":"IL-23-independent induction of IL-17 from gammadeltaT cells and innate lymphoid cells promotes experimental intraocular neovascularization","volume":"190","author":"Hasegawa","year":"2013","journal-title":"J Immunol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"611656","DOI":"10.3389\/fimmu.2021.611656","article-title":"IL-12p40\/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and Wnt","volume":"12","author":"Fiechter","year":"2021","journal-title":"Front Immunol"},{"key":"R45-20250526","article-title":"Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison","author":"Letarouilly","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"e58966","DOI":"10.1371\/journal.pone.0058966","article-title":"Regulation of IL-17A production is distinct from IL-17F in a primary human cell co-culture model of T cell-mediated B cell activation","volume":"8","author":"Melton","year":"2013","journal-title":"PLoS One"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2009.07.009","article-title":"Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase","volume":"31","author":"Gomez-Rodriguez","year":"2009","journal-title":"Immunity"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/eji.201948138","article-title":"Presence, function, and regulation of IL-17F-expressing human CD4(+) T cells","volume":"50","author":"Burns","year":"2020","journal-title":"Eur J Immunol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41590-018-0200-5","article-title":"An immunoregulatory and tissue-residency program modulated by c-MAF in human TH17 cells","volume":"19","author":"Aschenbrenner","year":"2018","journal-title":"Nat Immunol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni.1995","article-title":"Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5","volume":"12","author":"Yang","year":"2011","journal-title":"Nat Immunol"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4049\/jimmunol.1500286","article-title":"Transmembrane TNF-TNFR2 impairs Th17 differentiation by promoting Il2 expression","volume":"195","author":"Miller","year":"2015","journal-title":"J Immunol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"e20200288","DOI":"10.1084\/jem.20200288","article-title":"Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritis","volume":"217","author":"Kaaij","year":"2020","journal-title":"J Exp Med"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3899\/jrheum.190571","article-title":"Interleukin 17A and IL-17F expression and functional responses in rheumatoid arthritis and peripheral spondyloarthritis","volume":"47","author":"Chen","year":"2020","journal-title":"J Rheumatol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"s15","DOI":"10.25251\/skin.5.supp.15","article-title":"Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: results from a multicenter, randomized, double-blinded active comparator-controlled phase 3 trial (Be Sure)","volume":"5","author":"Warren","year":"2021","journal-title":"SKIN J Cutan Med"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u200ayear: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","article-title":"Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jdv.16126","article-title":"IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema","volume":"34","author":"Lauffer","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Investig Dermatol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.41169","article-title":"Interleukin-17 inhibition in spondyloarthritis is associated with subclinical gut microbiome perturbations and a distinctive interleukin-25-driven intestinal inflammation","volume":"72","author":"Manasson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-derived IL-17E contributes to inflammation in psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J Investig Dermatol"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.immuni.2015.03.008","article-title":"Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation","volume":"42","author":"Reynolds","year":"2015","journal-title":"Immunity"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00535-012-0591-2","article-title":"Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13","volume":"47","author":"Camelo","year":"2012","journal-title":"J Gastroenterol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00011-010-0200-x","article-title":"Differential dose effects of recombinant IL-25 on the development of dextran sulfate sodium-induced colitis","volume":"59","author":"McHenga","year":"2010","journal-title":"Inflamm Res"},{"issue":"(suppl 10)","key":"R74-20250526","article-title":"Interleukin-17D, a cytokine derived from stromal cells, attenuates joint inflammation","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"102435","DOI":"10.1016\/j.jaut.2020.102435","article-title":"Selective targeting of PI3Kdelta suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases","volume":"111","author":"Chen","year":"2020","journal-title":"J Autoimmun"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat Immunol"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41590-018-0134-y","article-title":"Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota","volume":"19","author":"Tang","year":"2018","journal-title":"Nat Immunol"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The cytokine IL-17A limits Th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural analysis reveals that the cytokine IL-17F forms a homodimeric complex with receptor IL-17RC to drive IL-17RA-independent signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:19:00Z","timestamp":1748294340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000805","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}